MediLink Therapeutics (Suzhou) Co., Ltd.

Quick facts

Phase 3 pipeline

• YL201 · Diabetes
  YL201 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• YL202 · Diabetes
  YL202 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

Phase 2 pipeline

• YL202 should be intravenously infused

Phase 1 pipeline

• YL201 and atezolizumab
• YL211
• YL217
• YL242
• YL242; 5-FU; LV
• YL242; Pembrolizumab
• YL242; Pembrolizumab; 5-FU

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• MediLink Therapeutics (Suzhou) Co., Ltd. portfolio CI brief
• MediLink Therapeutics (Suzhou) Co., Ltd. pipeline updates RSS